A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2025-07-10
Target enrollment:
Participant gender:
Summary
This study is designed to explore the safety and tolerability of RD14-01 for patients with
relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and
pharmacokinetics of RD14-01 in patients.